Use of PSMA PET/CT imaging before salvage radiotherapy was linked to improved survival for patients with BCR prostate cancer ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® ...

GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.

Scientists in the Netherlands discovered a new pair of salivary glands in the human throat while testing a cancer scan.